TCT 2023 | ISAR-DESIRE 3: 10-Year Results

In-stent restenosis (ISR) remains the primary limitation of percutaneous treatment for coronary artery disease. The strategy to address this limitation involves the use of drug-eluting stents (DES) or drug-coated balloons (DCB), both of which have proven to be effective and safe therapeutic alternatives.

TCT 2023 | SWEDEHEART, evolución  a 5 años

Despite current recommendations, treating ISR continues to be a challenge, and clinical trial evidence is limited. 

The objective of the Prospective Randomized ISAR-DESIRE 3 Study was to investigate the long-term incidence of recurrent revascularization after the treatment of ISR with drug-eluting stents.

The primary endpoint (PEP) was the need for repeat target lesion revascularization (R-TLR), defined as any repeated revascularization procedure over the 10-year follow-up.

A total of 402 patients were randomized to receive treatment with plain balloon (PB), DCB, or DES. At 10 years, R-TLR was required for 204 lesions, of which 82 were in the PB group, 70 in the DCB group, and 52 in the DES group. During the first year of follow-up, the risk of R-TLR was reduced with the use of DCB (hazard ratio [HR] = 0.36 [95% confidence interval (CI): 0.24-0.54]) and DES (HR = 0.23 [0.14-0.38]) compared with PB.

Read also: TCT 2023 | VIVA Trial: TAVR vs. SAVR in Patients with Severe Aortic Stenosis and Small Aortic Annulus.

After the first year, the risk of R-TLR was reduced non-significantly with DCB (HR = 0.77 [0.51-1.16]) and significantly with DES (HR = 0.61 [0.39-0.95]). The risk of DCB versus DES was similar during (HR = 1.54 [0.89-2.69]) and after 1 year (HR = 1.26 [0.82 – 1.92]).

Conclusion

In summary, the total number of R-TLR events after 10 years of DES-ISR treatment is high. The use of DCB and, in particular, of DES, are both alternatives to reduce the need for initial revascularization and recurrent revascularization compared with PB.

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Recurrent Revascularization at 10 Years after Percutaneous Treatment of Drug Eluting Stent Restenosis.

Reference: Tobias Koch, MD et al TCT 2023.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EMERALD II: Non-Invasive Coronary Anatomy and Physiology (CCTA) in ACS Prediction

Despite steady progress in secondary prevention and medical treatment optimization (OMT), acute coronary syndrome (ACS) remains one of the leading causes of cardiovascular morbimortality....

Left or Right Transradial Approach? Comparing Radiation Exposure in Coronary Procedures

Radiation exposure during percutaneous procedures is a problem both for patients and operators. The transradial is currently the preferred approach, vs. femoral; however, whether...

Dual Antiplatelet Therapy in Diabetic Patients with AMI: De-Escalation Strategy

Diabetes Mellitus (DM) is a common comorbidity in patients hospitalized for acute coronary syndrome (ACS) of increasing prevalence over the last decade, associated with...

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

Moderate to severe mitral valve regurgitation (MR) continues is still a high prevalence condition with bad prognosis, particularly among the elderly with left ventricular...

EMERALD II: Non-Invasive Coronary Anatomy and Physiology (CCTA) in ACS Prediction

Despite steady progress in secondary prevention and medical treatment optimization (OMT), acute coronary syndrome (ACS) remains one of the leading causes of cardiovascular morbimortality....

Impact of Balloon Post-Dilation on the Long-Term Durability of Bioprostheses after TAVR

Balloon post-dilation (BPD) during transcatheter aortic valve replacement (TAVR) allows for the optimization of prosthesis expansion and the reduction of residual paravalvular aortic regurgitation....